|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5580756A
(en)
|
1990-03-26 |
1996-12-03 |
Bristol-Myers Squibb Co. |
B7Ig fusion protein
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
DK0584266T3
(da)
|
1991-05-06 |
2003-12-29 |
Us Gov Health & Human Serv |
Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
|
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
|
DE69519521T2
(de)
|
1994-10-03 |
2001-06-28 |
The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
JPH11514853A
(ja)
|
1995-09-08 |
1999-12-21 |
ジエンザイム コーポレイション |
遺伝子治療のための改良されたａａｖベクター
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
US20030171551A1
(en)
|
1997-01-31 |
2003-09-11 |
Joseph D. Rosenblatt |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
AU751659B2
(en)
|
1997-05-02 |
2002-08-22 |
Genentech Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
US6635472B1
(en)
|
1997-08-15 |
2003-10-21 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
CA2304168A1
(en)
|
1997-09-19 |
1999-04-01 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
NZ509974A
(en)
|
1998-08-07 |
2003-10-31 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2364997A3
(en)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
EP1173204B1
(en)
|
1999-04-30 |
2010-04-21 |
The Trustees Of The University Of Pennsylvania |
Mutant human cd80 and compositions for and methods of making and using the same
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
JP4827353B2
(ja)
|
1999-08-09 |
2011-11-30 |
ターゲティッド ジェネティクス コーポレイション |
鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
EP1242116A2
(en)
|
1999-12-22 |
2002-09-25 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
BR0107736A
(pt)
|
2000-01-21 |
2002-11-19 |
Biovex Ltd |
Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US7094875B2
(en)
|
2000-06-23 |
2006-08-22 |
Maxygen, Inc. |
Co-stimulatory polypeptides
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
CA2413857C
(en)
|
2000-06-28 |
2010-04-27 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
JP2004517806A
(ja)
|
2000-07-03 |
2004-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
GB0021976D0
(en)
|
2000-09-07 |
2000-10-25 |
Optomed As |
Multi-parameter fiber optic probes
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
CA2442648C
(en)
|
2001-05-11 |
2012-10-16 |
Pro-Virus, Inc. |
Oncolytic virus therapy
|
|
EP1497426A2
(en)
*
|
2001-06-22 |
2005-01-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
CA2452517A1
(en)
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
CA2468258C
(en)
|
2001-11-30 |
2011-10-11 |
Jeffrey Schlom |
Peptide agonists of prostate-specific antigen, and uses therefor
|
|
CA2479763A1
(en)
|
2002-03-27 |
2003-10-09 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
EP1539230A4
(en)
|
2002-06-21 |
2007-10-31 |
Wellstat Biologics Corp |
ADMINISTRATION OF THERAPEUTIC VIRUSES
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
EP1549756A4
(en)
|
2002-09-09 |
2006-05-10 |
Univ Tennessee Res Foundation |
RECOMBINANT MUTANTS OF RHABDOVIRUS AND METHOD OF USE THEREOF
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
PL212899B1
(pl)
|
2002-12-16 |
2012-12-31 |
Genentech Inc |
Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
|
|
ATE417115T1
(de)
|
2003-03-27 |
2008-12-15 |
Ottawa Health Research Inst |
Mutante vesicular stomatitis viren und deren verwendungen
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
AU2004289953B2
(en)
|
2003-06-18 |
2008-09-25 |
Genelux Corporation |
Modified recombinant vaccina viruses and other microorganisms, uses thereof
|
|
EP2298926A1
(en)
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
EP1694852B1
(en)
|
2003-11-17 |
2010-10-13 |
Crusade Laboratories Limited |
Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
BRPI0417107A
(pt)
|
2003-12-19 |
2007-02-06 |
Genentech Inc |
fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
|
|
EP2067789A1
(en)
|
2004-04-13 |
2009-06-10 |
F. Hoffmann-La Roche Ag |
Anti-P selectin antibodies
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
SI2471813T1
(sl)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimirane Fc variante
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ４抗体
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
CA2611056C
(en)
|
2005-06-01 |
2016-06-28 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
EP1909849B1
(en)
|
2005-06-23 |
2013-08-07 |
The University Of Houston |
Use of mutant herpes simplex virus-2 for cancer therapy
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
JP5539718B2
(ja)
|
2006-07-21 |
2014-07-02 |
カリフォルニア インスティテュート オブ テクノロジー |
樹状細胞の免疫付与用の、標的特異的な遺伝子輸送
|
|
EP2415783B1
(en)
|
2006-10-16 |
2016-12-14 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
EP2114420B1
(en)
|
2007-02-16 |
2016-01-27 |
Virttu Biologics Limited |
Herpes simplex viruses and methods of viral replication
|
|
EP2141997B1
(en)
|
2007-03-30 |
2012-10-31 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
CA2690627C
(en)
|
2007-06-15 |
2014-12-02 |
Genelux Corporation |
Microorganisms for imaging and/or treatment of tumors
|
|
CN101784564B
(zh)
|
2007-07-13 |
2014-07-02 |
约翰霍普金斯大学 |
B7-dc变体
|
|
EP2173368A1
(en)
|
2007-07-18 |
2010-04-14 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
EP2212696B1
(en)
|
2007-10-25 |
2013-12-04 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
EP2612868B1
(en)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
JP2011505795A
(ja)
|
2007-11-27 |
2011-03-03 |
ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド |
バリアントｎｆｋｂｉｂの癌関連エピトープに対する抗体およびその使用
|
|
ES2664988T3
(es)
|
2007-12-11 |
2018-04-24 |
The University Of North Carolina At Chapel Hill |
Vectores retrovirales modificados del tracto de polipurinas
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
PL3208612T3
(pl)
|
2008-04-09 |
2020-03-31 |
Genentech, Inc. |
Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
|
|
EP2300023A2
(en)
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
EP2662383A1
(en)
|
2008-08-25 |
2013-11-13 |
Amplimmune, Inc. |
PD-I antagonists and methods for treating infectious disease
|
|
JP5798919B2
(ja)
|
2008-08-25 |
2015-10-21 |
アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． |
Ｐｄ−１アンタゴニストの組成物および使用方法
|
|
EP2398466B1
(en)
|
2008-11-24 |
2021-02-17 |
Massachusetts Institute of Technology |
Methods and compositions for localized nanoparticle delivery to a tumor
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
JP2013500015A
(ja)
|
2009-07-24 |
2013-01-07 |
イミューン デザイン コーポレイション |
シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
|
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
CN104826106B
(zh)
|
2009-09-30 |
2019-01-11 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
KR20130049775A
(ko)
|
2010-03-12 |
2013-05-14 |
애브비 바이오테라퓨틱스 인크. |
Ｃｔｌａ４ 단백질 및 이의 용도
|
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JP5972915B2
(ja)
|
2011-03-16 |
2016-08-17 |
アムジエン・インコーポレーテツド |
Ｆｃ変異体
|
|
US9044420B2
(en)
|
2011-04-08 |
2015-06-02 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
CN102836441B
(zh)
|
2011-06-24 |
2019-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
MY180616A
(en)
|
2011-06-30 |
2020-12-03 |
Genzyme Corp |
Inhibitors of t-cell activation
|
|
US8956619B2
(en)
*
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
WO2013130683A2
(en)
|
2012-02-27 |
2013-09-06 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
|
CN104583231B
(zh)
|
2012-03-30 |
2021-02-26 |
免疫设计公司 |
具有对表达dc-sign的细胞改善的转导效率的慢病毒载体粒子
|
|
AU2013260172B2
(en)
|
2012-05-11 |
2017-11-23 |
Medimmune Limited |
CTLA-4 variants
|
|
EP2858673A4
(en)
|
2012-06-06 |
2016-06-22 |
Oncomed Pharm Inc |
BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
TW201439115A
(zh)
|
2012-12-04 |
2014-10-16 |
Oncomed Pharm Inc |
使用結合劑之免疫治療
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US20160017041A1
(en)
|
2013-03-15 |
2016-01-21 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
MX384142B
(es)
|
2013-07-16 |
2025-03-14 |
Genentech Inc |
Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
EP3094647A1
(en)
|
2014-01-15 |
2016-11-23 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
WO2015120363A1
(en)
|
2014-02-10 |
2015-08-13 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
AU2015289773A1
(en)
|
2014-07-15 |
2017-02-02 |
Immune Design Corp. |
Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
|
|
CR20170014A
(es)
|
2014-07-16 |
2017-10-17 |
Hoffmann La Roche |
Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
|
|
DK3177640T3
(da)
|
2014-08-08 |
2020-08-10 |
Univ Leland Stanford Junior |
Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder
|
|
KR20160021586A
(ko)
|
2014-08-18 |
2016-02-26 |
지경민 |
시력교정용 필터 및 이를 이용한 시력교정방법
|
|
SG10201901735XA
(en)
|
2014-09-03 |
2019-03-28 |
Bavarian Nordic As |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
JP2018501302A
(ja)
|
2014-11-06 |
2018-01-18 |
チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター |
癌及び自己免疫疾患のための免疫療法剤
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
US10953045B2
(en)
|
2015-04-02 |
2021-03-23 |
Cancure Limited |
Agents and compositions for eliciting an immune response
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
KR20240046641A
(ko)
|
2015-04-17 |
2024-04-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
조율가능한 친화성을 갖는 면역조절 단백질
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
CA2987410A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
|
KR102761886B1
(ko)
|
2015-07-30 |
2025-02-06 |
마크로제닉스, 인크. |
Pd-1-결합 분자 및 그것의 사용 방법
|
|
WO2017023779A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
EP3328363A4
(en)
|
2015-07-31 |
2019-08-21 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHOD FOR IMMUNOMODULATION
|
|
CA2995462A1
(en)
|
2015-08-12 |
2017-02-16 |
First Quality Packaging Solutions, Llc |
Container and method of forming the same
|
|
WO2017029389A1
(en)
|
2015-08-20 |
2017-02-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
B7-h1 fusion polypeptides for treating and preventing organ failure
|
|
KR20180054713A
(ko)
|
2015-09-14 |
2018-05-24 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
|
|
MX2018003936A
(es)
|
2015-10-02 |
2018-07-06 |
Symphogen As |
Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
|
|
MX2018005517A
(es)
|
2015-11-02 |
2018-11-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
|
|
AU2017226269B2
(en)
|
2016-03-02 |
2021-10-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
MA43551A
(fr)
|
2016-04-15 |
2018-11-07 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
|
|
KR102764225B1
(ko)
|
2016-04-15 |
2025-02-07 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
KR20190019068A
(ko)
|
2016-05-18 |
2019-02-26 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
EP3526241A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Il15/il15r heterodimeric fc-fusion proteins
|
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
IL268781B2
(en)
|
2017-03-16 |
2025-09-01 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
EP3596116B1
(en)
|
2017-03-16 |
2023-09-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|